7 Hills Pharma

7 Hills Pharma is a clinical-stage pharmaceutical company based in Houston, Texas. With a team of eleven employees, the company has generated $2.5 million in revenue. 7 Hills Pharma focuses on developing innovative oral immune stimulants to enhance existing immunotherapies. The company's primary focus is on creating first-in-concept, oral immune stimulants designed to boost the effectiveness of various immunotherapies. These stimulants target integrins LFA-1 and VLA-4, aiming to improve the treatment of drug-resistant solid tumors and prevent infectious diseases. 7 Hills Pharma has demonstrated promising results in preclinical models, showing its compounds can enhance prophylactic vaccines for diseases like influenza, COVID-19, Tuberculosis, and Chagas disease, as well as checkpoint inhibitors for solid tumors. Their lead molecule, 7HP349, has successfully completed a Phase I, first-in-human clinical trial, proving its oral bioavailability and exceptional safety profile at doses exceeding therapeutic levels. For more information about 7 Hills Pharma and its groundbreaking research, please visit their website at 7hillspharma.com.